Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Kymera Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 0.0%. For fiscal 2025 it was 0.0%, against 0.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.0% | +0.0 |
| FY2024 | Dec 31, 2024 | 0.0% | +0.0 |
| FY2023 | Dec 31, 2023 | 0.0% | +0.0 |
| FY2022 | Dec 31, 2022 | 0.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 0.0% | +0.0 |
| Q1 FY2026 | Mar 31, 2026 | 0.0% | +0.0 |
| Q4 FY2025 | Dec 31, 2025 | 0.0% | +0.0 |
| Q3 FY2025 | Sep 30, 2025 | 0.0% | +0.0 |
| Q2 FY2025 | Jun 30, 2025 | 0.0% | +0.0 |
| Q1 FY2025 | Mar 31, 2025 | 0.0% | +0.0 |
| Q4 FY2024 | Dec 31, 2024 | 0.0% | – |
| Q3 FY2024 | Sep 30, 2024 | 0.0% | – |
| Q2 FY2024 | Jun 30, 2024 | 0.0% | – |
| Q1 FY2024 | Mar 31, 2024 | 0.0% | – |
See a number that looks wrong?